[EN] BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF<br/>[FR] ACIDES BÊTA-AMINÉS SUBSTITUÉS EN BÊTA ET ANALOGUES À UTILISER EN TANT QU'AGENTS DE CHIMIOTHÉRAPIE ET LEURS UTILISATIONS
申请人:QUADRIGA BIOSCIENCES INC
公开号:WO2017024009A1
公开(公告)日:2017-02-09
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
[EN] 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS<br/>[FR] 2-CYANOPYRROLES ET LEURS ANALOGUES EN TANT QU'INHIBITEURS DE DIPEPTIDYLPEPTIDASE-IV (DP-IV)
申请人:NOVO NORDISK AS
公开号:WO2004089362A1
公开(公告)日:2004-10-21
The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV having the formula I: (I) The invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of such compounds for the manufacture of medicaments for treating diseases that are associated with proteins which are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity.
Thermal Syntheses of Polypeptides from<i>N</i>-Boc-Amino Acid(Aspartic Acid,β-Aminoglutaric Acid) Anhydrides
作者:Toratane Munegumi、Yan-Qing Meng、Kaoru Harada
DOI:10.1246/cl.1988.1643
日期:1988.10.5
N-t-Butyloxycarbonyl-amino acid(aspartic acid:Asp, glutamic acid:Glu, β-aminoglutaricacid: β-Agl)anhydrides were deprotected upon heating at temperatures slightly higher than the melting points of these compounds and polypeptides were synthesized easily in high yield.
LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE
申请人:LEGOCHEM BIOSCIENCES, INC.
公开号:US20220226496A1
公开(公告)日:2022-07-21
The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.
Electrochemical Synthesis of a Sitagliptin Precursor
作者:Elisabeth K. Oehl、Paul T. Jirsch、Jasmin Hammes、Andreas Stenglein、María Méndez、Sven Ruf、Siegfried R. Waldvogel
DOI:10.1021/acs.joc.4c00428
日期:——
A novel synthesis of sitagliptin based on a redox-active ester derived from the chiral pool is reported. The key step is an electrochemical nickel-catalyzed sp2-sp3 cross-coupling reaction using inexpensive nickel foam in an undivided cell. It was successfully applied to 21 examples in up to 88% yield. These sitagliptin-analogue precursors could potentially interact with the DPP4 enzyme. A full synthesis